<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-2" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>GABA Receptor Positive Allosteric Modulators</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Edwards</surname>
            <given-names>Zachary</given-names>
          </name>
          <aff>Campbell University School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zachary Edwards declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-2.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">GABA receptor-positive allosteric modulators, encompassing benzodiazepines and barbiturates, are pivotal in addressing diverse medical conditions such as seizures, anxiety, alcohol withdrawal, sedation, and muscle spasms. This educational initiative is tailored for the multidisciplinary healthcare team caring for patients with these conditions. The program meticulously explores the indications, mechanisms of action, and contraindications of GABA-positive allosteric modulators, shedding light on their specific roles in seizure control, anxiolysis, alleviation of alcohol withdrawal symptoms, sedation induction, and mitigation of muscle spasms.</p>
        <p>Participants in this educational activity acquire an&#x000a0;enhanced understanding of the pharmacodynamics and pharmacokinetics of GABA-positive allosteric modulators, encompassing potential off-label applications, dosing strategies, monitoring parameters, and pertinent drug interactions. The aim is to empower healthcare professionals with the knowledge required to make informed decisions, ensure judicious prescribing practices, and optimize patient care in the management of seizures, anxiety disorders, alcohol withdrawal, sedation, and muscle spasms, among other related conditions. The content provides an in-depth exploration of the mechanism of action and adverse event profile, facilitating the enhancement of clinical expertise in utilizing these medications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the suitable clinical scenarios and patient profiles where GABA-positive allosteric modulators are appropriate for managing conditions such as seizures, anxiety, alcohol withdrawal, sedation, and muscle spasms.</p></list-item><list-item><p>Screen and conduct comprehensive patient assessments to identify individuals who might benefit from GABA-positive allosteric modulators, considering their medical history and potential interactions with other medications.</p></list-item><list-item><p>Select the most suitable GABA-positive allosteric modulator based on patient-specific characteristics and the nature of the condition being treated.</p></list-item><list-item><p>Implement strategies&#x000a0;within an interprofessional healthcare team to coordinate care plans, share information, and ensure comprehensive patient management using GABA-positive allosteric modulators.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=2&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=2">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-2.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The GABA-positive allosteric modulators in clinical practice fall under&#x000a0;5 categories: benzodiazepines, barbiturates, ethanol, non-benzodiazepine hypnotics, and induction anesthetics. Generally, these drugs will cause sedation, anticonvulsant, anxiolytic, and muscle relaxant effects. Some&#x000a0;specific indications of each drug class appear in outline form below. Not all class members have the same approved indications, so clinicians should consult appropriate resources before prescribing, ordering, or administering any of these agents.&#x000a0;</p>
        <p>Benzodiazepines consist of drugs such as alprazolam, lorazepam, diazepam, etc. Many of these agents are recognizable by the suffixes "-zolam" and "-pam".<xref ref-type="bibr" rid="article-2.r1">[1]</xref><xref ref-type="bibr" rid="article-2.r2">[2]</xref>&#x000a0;These drugs are now recommended for the short-term management of insomnia, panic disorder, and anxiety due to the risk of physical and psychological tolerance and dependence. They are also helpful as abortive medications for generalized clonic-tonic seizures and seizure prophylaxis in alcohol withdrawal. Midazolam and lorazepam are also used for light sedation in short outpatient or interventional radiology procedures. Drugs in this class exert their action by increasing the effects of an agonist when they achieve potentiation.<xref ref-type="bibr" rid="article-2.r1">[1]</xref></p>
        <p>Most general anesthetics are positive allosteric modulators of GABA-A receptors (GABAAR). Positive allosteric modulators increase the frequency with which the chlorine channel opens when an agonist binds to its site on the GABA receptor. This action results in an increase in the chloride ion concentration in the postsynaptic neuron and causes immediate hyperpolarization of this neuron, making it less excitable and thus inhibiting the possibility of an action potential. Drugs that act like GABA agonists, the benzodiazepines, are widely used to manage seizures, muscle spasms, insomnia, delirium, and anxiety.<xref ref-type="bibr" rid="article-2.r3">[3]</xref><xref ref-type="bibr" rid="article-2.r4">[4]</xref>&#x000a0;Among the&#x000a0;GABAAR agonists used in anesthesia practice and sedation include propofol, etomidate, methohexital, thiopental, isoflurane, sevoflurane, and desflurane.<xref ref-type="bibr" rid="article-2.r3">[3]</xref></p>
        <p>Barbiturates were once used to induce sedation but are now used for short-term management of insomnia, seizure prevention, and euthanasia. Phenobarbital specifically can be used in neonatal jaundice.&#x000a0;Phenobarbital is also a recognized drug of misuse. Ethanol is a potential drug of abuse.&#x000a0;Medically, alcohol has a specific application in the septal ablation of patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Intravenous anesthetics such as etomidate, propofol, midazolam, and thiopental are useful for inducing sedation in surgical procedures.<xref ref-type="bibr" rid="article-2.r3">[3]</xref><xref ref-type="bibr" rid="article-2.r5">[5]</xref><xref ref-type="bibr" rid="article-2.r6">[6]</xref><xref ref-type="bibr" rid="article-2.r4">[4]</xref></p>
        <p>Non-benzodiazepine sedative/hypnotic drugs include zolpidem, zopiclone, and zaleplon (the so-called "Z-drugs"), which are used to treat insomnia. They generally have a lower threshold for misuse than benzodiazepines and, in many scenarios, have replaced them as sleep aids.<xref ref-type="bibr" rid="article-2.r7">[7]</xref></p>
      </sec>
      <sec id="article-2.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The target of GABA-positive allosteric modulators (PAM) is the GABA-A receptor. The GABA-A receptor is commonly composed of&#x000a0;2 &#x003b1; (alpha) subunits,&#x000a0;2 &#x003b2; (beta) subunits, and&#x000a0;1 &#x003b3; (gamma) subunit that form a pentamer around the ligand-gated chloride channel. Depending on where the GABA-A receptor is in the CNS, the composition of the subunits in the GABA-A receptor will vary.<xref ref-type="bibr" rid="article-2.r1">[1]</xref></p>
        <p>The GABA-A receptor is activated when its ligand, GABA, binds to the ligand-binding site. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter of the central nervous system. When GABA binds to the ligand site of the GABA-A receptor, the channel opens to allow chloride into the cell. This action results in hyperpolarization of the cell and subsequently diminished action potential, preventing the release of excitatory neurotransmitters.<xref ref-type="bibr" rid="article-2.r1">[1]</xref></p>
        <p>Drugs in this class exert their action by increasing an agonist's effects when achieving potentiation. Most general anesthetics are PAMs of GABA-A receptors. Positive allosteric modulators increase the frequency with which the chlorine channel opens when an agonist binds to its site on the GABA receptor. This action increases the Cl<sup>-</sup> ion concentration in the postsynaptic neuron and causes immediate hyperpolarization of this neuron, making it less excitable and thus inhibiting the possibility of an action potential. Drugs that act like GABA agonists, the benzodiazepines, are widely used to manage seizures, muscle spasms, insomnia, delirium, and anxiety.<xref ref-type="bibr" rid="article-2.r1">[1]</xref><xref ref-type="bibr" rid="article-2.r6">[6]</xref><xref ref-type="bibr" rid="article-2.r4">[4]</xref></p>
        <p>Most general anesthetics are positive allosteric modulators (PAM) of the GABA-A receptor. Positive allosteric modulators presumably work by enhancing the frequency of opening of the chloride channel when an agonist binds to its receptor site on the GABA neurons. This change increases the concentration of Cl<sup>-</sup> ions in the postsynaptic neurons, which results in immediate hyperpolarization of the neuron.&#x000a0;The&#x000a0;result is that the neuron is less excitable and unable to generate an action potential.<xref ref-type="bibr" rid="article-2.r1">[1]</xref><xref ref-type="bibr" rid="article-2.r6">[6]</xref><xref ref-type="bibr" rid="article-2.r4">[4]</xref></p>
        <p>Benzodiazepines increase the frequency of chloride channel opening, which facilitates GABA-A receptor potential and reduces neuronal firing. Barbiturates work by increasing the time chloride channels&#x000a0;remain open, facilitating GABA-A receptor potential and reducing neuronal firing. Ethanol helps potentiate GABA receptors.<xref ref-type="bibr" rid="article-2.r1">[1]</xref><xref ref-type="bibr" rid="article-2.r2">[2]</xref><xref ref-type="bibr" rid="article-2.r6">[6]</xref></p>
        <p>The nonbenzodiazepines function as positive allosteric modulators of GABA receptors. Similarly&#x000a0;to benzodiazepines, they bind and activate the benzodiazepine receptor site complex.&#x000a0;</p>
        <p>Alcohol (ethanol) appears to be a GABA-A receptor agonist. GABA is one of the significant inhibitory neurotransmitters in the central nervous system, and GABA-like drugs are often used therapeutically to decrease muscle spasms. The belief is that alcohol mimics the actions of GABA in the brain by binding to GABA-A receptors and inhibiting the generation of nerve action potentials/neuronal signaling.<xref ref-type="bibr" rid="article-2.r1">[1]</xref></p>
      </sec>
      <sec id="article-2.s4" sec-type="Administration">
        <title>Administration</title>
        <p>GABA-positive allosteric modulators are available for administration in various dosage forms. Benzodiazepine can be administered orally, parenterally, or rectally. Non-benzodiazepine hypnotics are available in oral formulations (capsules, tablets). Barbituates can be administered orally, parenterally, or rectally. Anesthetics such as etomidate and thiopental can be administered intravenously.<xref ref-type="bibr" rid="article-2.r1">[1]</xref><xref ref-type="bibr" rid="article-2.r3">[3]</xref><xref ref-type="bibr" rid="article-2.r8">[8]</xref><xref ref-type="bibr" rid="article-2.r9">[9]</xref></p>
      </sec>
      <sec id="article-2.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>GABA-positive allosteric modulators can have significant adverse effects. These depend on the exact agent/class.<xref ref-type="bibr" rid="article-2.r10">[10]</xref></p>
        <p>Barbiturates slow the central nervous system and cause sleepiness, euphoria, lack of restraint, and relief of anxiety. They can also cause memory impairment, poor judgment, and poor coordination. Other adverse events associated with barbiturates include irritability, paranoia, and suicidal ideation.</p>
        <p>Benzodiazepine GABA-positive allosteric modulators can cause sedation, dizziness, weakness, instability, and dependence. Paradoxical agitation may occur in&#x000a0;older patient populations. Barbiturate&#x000a0;GABA-positive allosteric modulators can cause sedation, respiratory depression, cardiovascular depression, and dependence. Ethanol&#x000a0;GABA-positive allosteric modulators can cause sedation, slurred speech, respiratory depression, cardiovascular depression, and dependence.<xref ref-type="bibr" rid="article-2.r11">[11]</xref><xref ref-type="bibr" rid="article-2.r12">[12]</xref></p>
        <p>Nonbenzodiazepine hypnotic agents can cause hallucinations and amnesia, particularly in larger doses. Reduced dosing is recommended for older patients to prevent adverse events.</p>
        <p>GABAAR anesthetics adverse event profiles can vary by agent. Propafol can cause dose-related cardiovascular depression, bradycardia, decreased sympathetic tone, decreased vascular resistance, and subsequent hypotension. Etomidate can cause shock and&#x000a0;is associated with higher rates of adrenal insufficiency and mortality in sepsis patients.<xref ref-type="bibr" rid="article-2.r13">[13]</xref>&#x000a0;Isoflurane can lead to malignant hypothermia, severe hyperkalemia, arrhythmias, and QT prolongation. Clinicians must familiarize themselves with the adverse effects of their particular agent.</p>
      </sec>
      <sec id="article-2.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Benzodiazepine GABA-positive allosteric modulators are contraindicated in patients who have had prior hypersensitivity reactions. Lorazepam contraindications include patients with acute narrow-angle glaucoma. Alprazolam is contraindicated with ketoconazole and itraconazole because of inhibition of&#x000a0;alprazolam metabolism, leading to increased serum drug levels. Barbiturate&#x000a0;GABA-positive allosteric modulators are contraindicated in patients who have had prior hypersensitivity reactions to barbiturate medications. They are also contraindicated in patients with latent porphyria or severe liver or respiratory disease.<xref ref-type="bibr" rid="article-2.r2">[2]</xref><xref ref-type="bibr" rid="article-2.r9">[9]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Because of the severe risk of misuse, abuse, addiction, and withdrawal, in 2020, the FDA required the Boxed Warning for all benzodiazepines to be updated. The FDA ruled that the current labeling for these medications does not include sufficient warning regarding the serious risks and harms associated with them so that they can be prescribed appropriately. This can lead to severe risks, especially when these drugs are used in conjunction with other agents. The FDA says that benzodiazepines, even at recommended doses, can result in overdose or death, especially when combined with other agents, including opioids, alcohol, or other illicit drugs. Physical dependence can also occur. Abrupt cessation can lead to withdrawal reactions, including life-threatening seizures.<xref ref-type="bibr" rid="article-2.r14">[14]</xref></p>
      </sec>
      <sec id="article-2.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients requiring treatment with&#x000a0;GABA-positive allosteric modulators require monitoring for central nervous system depression, respiratory depression, cardiovascular system depression, and signs of misuse, abuse, or dependence.<xref ref-type="bibr" rid="article-2.r2">[2]</xref><xref ref-type="bibr" rid="article-2.r9">[9]</xref></p>
      </sec>
      <sec id="article-2.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Symptoms of acute barbiturate intoxication include slurred speech, unsteady gait, and&#x000a0;sustained nystagmus. Mental signs of chronic intoxication include irritability, prior judgment, confusion, insomnia, and somatic complaints. Symptoms of barbiturate dependence are similar to&#x000a0;those of chronic alcoholism. Dependence&#x000a0;on barbiturates arises from repeated, continual use of a barbiturate or an agent&#x000a0;with a barbiturate-like effect, generally in amounts&#x000a0;exceeding therapeutic&#x000a0;dosing levels.&#x000a0;There is no direct antidote for barbiturate toxicity. In some extreme cases, dialysis can be used to remove the drug from the circulatory system.<xref ref-type="bibr" rid="article-2.r15">[15]</xref></p>
        <p>Patients overdosing on benzodiazepines should receive flumazenil immediately. Patients who overdose on barbiturates will need symptom management, such as respiratory and blood pressure assistance. Patients who present with ethanol overdose will receive symptom management, supportive care, intravenous fluids, and, in some cases, thiamine to prevent Wernicke's encephalopathy. Patients who present with ethanol poisoning require monitoring for central nervous depression and hypoglycemia.<xref ref-type="bibr" rid="article-2.r11">[11]</xref><xref ref-type="bibr" rid="article-2.r12">[12]</xref></p>
        <p>An ethanol blood alcohol concentration of 20 to 50 mg/dL reduces fine motor coordination. A blood alcohol concentration of 400 mg/dL can cause respiratory depression. Barbiturates are often used to detoxify chronic alcohol abusers, typically diazepam, sedating them to avoid delirium tremens.<xref ref-type="bibr" rid="article-2.r16">[16]</xref></p>
      </sec>
      <sec id="article-2.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Indications for GABA-positive allosteric modulators include a wide variety of clinical settings and require the efforts of an interprofessional healthcare team that includes physicians, advanced practice practitioners, nursing staff, and pharmacists.&#x000a0;Clinicians should pay careful attention to their patients when utilizing these medications due to their&#x000a0;potential for misuse, dependence, and severe multisystem organ failure. Clinicians must be well-versed in&#x000a0;GABA-positive allosteric modulator dosing, adverse effects, contraindications, and clinical indications. Nursing staff should monitor the patient carefully once therapy has been initiated, answer questions, and alert the prescriber to concerns. Pharmacists should verify dosing, watch for signs of potential misuse, perform medication reconciliation, and contact the prescriber should they notice any issues that may necessitate intervention by the clinician. These interprofessional examples demonstrate how this approach can help optimize therapy with these agents.<xref ref-type="bibr" rid="article-2.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-2.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=2&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=2">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/2/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=2">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-2.s11">
        <title>References</title>
        <ref id="article-2.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jembrek</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vlainic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>GABA Receptors: Pharmacological Potential and Pitfalls.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>34</issue>
            <fpage>4943</fpage>
            <page-range>4943-59</page-range>
            <pub-id pub-id-type="pmid">26365137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ripps</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Slaughter</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>GABA<sub>B</sub> receptor attenuation of GABA<sub>A</sub> currents in neurons of the mammalian central nervous system.</article-title>
            <source>Physiol Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28348006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brohan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goudra</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>The Role of GABA Receptor Agonists in Anesthesia and Sedation.</article-title>
            <source>CNS Drugs</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>845</fpage>
            <page-range>845-856</page-range>
            <pub-id pub-id-type="pmid">29039138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Dilber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stauber</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Ransom</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Barbiturate and benzodiazepine modulation of GABA receptor binding and function.</article-title>
            <source>Life Sci</source>
            <year>1986</year>
            <month>Nov</month>
            <day>24</day>
            <volume>39</volume>
            <issue>21</issue>
            <fpage>1969</fpage>
            <page-range>1969-76</page-range>
            <pub-id pub-id-type="pmid">2431244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santilli</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Specific hyposensitizing therapy in bronchial asthma and allergic rhinopathy].</article-title>
            <source>Folia Allergol (Roma)</source>
            <year>1970</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-40</page-range>
            <pub-id pub-id-type="pmid">5517224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ain</surname>
                <given-names>QU</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Omoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Torella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bulusu</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Pryde</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Glen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Differential Efficacy and Affinity of GABA<sub>A</sub> (&#x003b1;1/&#x003b1;2) Selective Modulators.</article-title>
            <source>Mol Pharm</source>
            <year>2016</year>
            <month>Nov</month>
            <day>07</day>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>4001</fpage>
            <page-range>4001-4012</page-range>
            <pub-id pub-id-type="pmid">27704838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McHugh</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Votaw</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Trapani</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National Survey on Drug Use and Health.</article-title>
            <source>Front Psychiatry</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1129447</fpage>
            <pub-id pub-id-type="pmid">36970272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Clinically applicable GABA receptor positive allosteric modulators promote &#x000df;-cell replication.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>23</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>374</fpage>
            <pub-id pub-id-type="pmid">28336918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korpi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Mattila</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wisden</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>L&#x000fc;ddens</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands.</article-title>
            <source>Ann Med</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-82</page-range>
            <pub-id pub-id-type="pmid">9375983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budnitz</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Shehab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lovegrove</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>US Emergency Department Visits Attributed to Medication Harms, 2017-2019.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Oct</month>
            <day>05</day>
            <volume>326</volume>
            <issue>13</issue>
            <fpage>1299</fpage>
            <page-range>1299-1309</page-range>
            <pub-id pub-id-type="pmid">34609453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MULLAN</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>PLATTS</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>RIDGWAY</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>BARBITURATE INTOXICATION.</article-title>
            <source>Lancet</source>
            <year>1965</year>
            <month>Mar</month>
            <day>27</day>
            <volume>1</volume>
            <issue>7387</issue>
            <fpage>705</fpage>
            <pub-id pub-id-type="pmid">14258561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ISBELL</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Addiction to barbiturates and the barbiturate abstinence syndrome.</article-title>
            <source>Ann Intern Med</source>
            <year>1950</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-21</page-range>
            <pub-id pub-id-type="pmid">15426096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Balle</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>GABA<sub>A</sub> receptors as targets for anaesthetics and analgesics and promising candidates to help treat coronavirus infections: A mini-review.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>443</fpage>
            <page-range>443-451</page-range>
            <pub-id pub-id-type="pmid">36165608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pergolizzi</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>LeQuang</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Raffa</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines: Thinking outside the black box.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>554</fpage>
            <page-range>554-559</page-range>
            <pub-id pub-id-type="pmid">33347636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Page</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Roehr</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Use of Peritoneal Dialysis in Phenobarbitone Toxicity in a Critically Unwell Neonate.</article-title>
            <source>Neonatology</source>
            <year>2018</year>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-121</page-range>
            <pub-id pub-id-type="pmid">29169160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-2.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gopaldas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Padyana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Practice Patterns in the Diagnosis and Management of Alcohol Withdrawal Syndrome in Indian Intensive Care Units.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>816</fpage>
            <page-range>816-820</page-range>
            <pub-id pub-id-type="pmid">37936810</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
